CMN Weekly (14 May 2021)

Some of the best links we picked up around the internet

By: Gorm Palmgren - May. 14, 2021

Top pick

  • Efficient and gentle delivery of Cas9–sgRNA RNPs into cells has been obtained by a new technology called progressive mechanoporation (PM). PM is based on a polymer biochip that contains a series of microchannels where each microchannel is narrower than the previous one. When cells are passed through these channels, pores are temporarily formed in their cell membranes. The method is also applicable for the introduction of drugs and other small molecules.

Research

Industry

Quarter 1 industry update highlights

  • Precision BioSciences has reported first-quarter 2021 financial results and business updates. The company has begun its PBCAR19B phase 1 study on allogeneic CAR T cells and is advancing on three other phase 1/2a clinical studies. It is also about to file an IND application for treatment of R/R multiple myeloma.
  • Beam Therapeutics reports a substantial increase in first-quarter R&D spending of $190.1 million, up from $21.5 in 2020. The company also reported new promising data on its proprietary lipid nanoparticle (LNP) formulation and base editing programmes.

COVID-19

Reviews

Conferences

Opinion and People

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

CLINICAL TRIALS
Non-small Cell Lung Cancer,NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine